Dr. Fritiof Pontén has a solid experience of drug development gathered during 17 years at AstraZeneca. He has been active in a wide range of drug project activities ranging from all discovery phases to late stage preclinical studies enabling First Time in Man. Besides his work in drug projects Fritiof has been active within organizational and technical development. He has built up and headed a facility and organisation for scale up of drug candidates from mg to kg during the last 10 years. Fritiof has grown his team from scratch and introduced novel capabilities such as continuous processing, bio-catalysis and asymmetric catalysis in the daily deliveries.
In his role as Senior Scientist and later Associate Principle Scientist Fritiof was active in drug projects ranging from early Lead Discovery to late stage Lead Optimization. He introduced multi parallell synthesis in combination with a scaffold hopping within a antiarrythmia lead optimization project. This resulted in the invention of AZD7009 and AZD1305, the first two fully non-proarrythmic oral drugs that went into man.